Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Immune checkpoint inhibitors induce durable responses in some patients with advanced cancer but may simultaneously trigger autoinflammatory immune-related adverse events (irAE). The pathogenesis of irAEs may relate to genetic predisposition, environmental insults, or tumor-host interactions. Elevated expression of certain cytokines may signal subclinical inflammation that evolves into severe irAEs with treatment.See related article by Lim et al., p. 1557.

Keyphrases

advanced cancer
palliative care
oxidative stress
poor prognosis
gene expression
genome wide
early onset
drug induced
copy number
long non coding rna
combination therapy
smoking cessation